en
svNotice of annual general meeting of Xspray Pharma AB (publ)
Regulatory press release 2019-04-24
The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, are summoned to the annual
general meeting on Thursday 23 May 2019 at 11.00 CEST at Advokatfirman Vinge’s office on Stureplan
8 in Stockholm. Registration starts at 10.30 CEST.
Right to attend the annual general meeting
Shareholders who wish to attend the annual general meeting must:
– be registered in the share register maintained by Euroclear Sweden AB on Friday 17 May 2019,
and must also
– notify the company of their intention to attend the meeting, no later than Friday 17 May 2019.
The notification must be made in writing by e-mail to generalmeeting@xspray.com, or by post to
Xspray Pharma, ”General meeting”, Råsundavägen 12, SE-169 67 Solna, Sweden. The notification must
state the shareholder’s name, personal identity number/registration number, shareholding, address,
day time telephone number and information about the attendance of any assistants (maximum two)
and, if applicable, information about any proxies. Information submitted in connection with the
notification will be computerised and used exclusively for the annual general meeting. See below for
additional information on the processing of personal data.
Proxy
Shareholders represented by proxy must submit a dated power of attorney. If the power of attorney
is executed by a legal person a certified copy of the certificate of registration or equivalent should be
attached. The power of attorney and the certificate of registration may not be older than one year,
however, the power of attorney may be older provided that the power of attorney according to its
wording is valid for a longer period, although, not more than five years. The original power of attorney
and the certificate of registration should be sent to the company at the address mentioned above well
in advance of the general meeting. A proxy form is available at the company’s webpage,
www.xspraypharma.com, and will also be sent to shareholders who so request and state their postal
address.
Nominee-registered shares
Shareholders whose shares are registered in the name of a nominee through a bank or a securities
institution must re-register their shares in their own names in order to be entitled to attend the general
meeting. Such registration, which may be temporary, must be duly effected in the share register
maintained by Euroclear Sweden AB on Friday 17 May 2019, and the shareholders must therefore
advise their nominees well in advance of this date.
Number of shares and votes
As per the date of this notice there are a total of 15,076,460 shares outstanding for the company that
entitle to one vote per share at the annual general meeting. As per the date of this notice the company
holds no treasury shares.
Proposed agenda
1. Election of a chairman of the meeting
2. Preparation and approval of the voting register
3. Election of one or two persons to attest the minutes
4. Determination of whether the meeting was duly convened
5. Approval of the agenda
6. Presentation of the annual report and auditor’s report and, where applicable, the consolidated
financial statements and auditor’s report for the group
7. Resolutions regarding
(a) adoption of the income statement and balance sheet and, where applicable, the
consolidated income statement and consolidated balance sheet,
(b) allocation of the company’s profit or loss according to the adopted balance sheet,
(c) discharge from liability for board members and the managing director.
8. Determination of the number of board members and auditors
9. Determination of fees for the board of directors and the auditors
10. Election of the board of directors and auditors
11. Resolution on principles for the appointment of the nomination committee
12. Resolution to authorise the board of directors to issue new shares
13. Closing of the meeting
Item 1, 8-10 – The nomination committee’s proposal to the annual general meeting 2019
The nomination committee of Xspray Pharma AB (publ), which consists of Michael Wolff Jensen
(chairman of the board), Gillis Cullin (Östersjöstiftelsen), Anders Bladh (Ribbskottet AB) and Niclas
Eriksson (Niclas Eriksson Family and holding companies), proposes the following:
– that Dain Hård Nevonen, lawyer at Advokatfirman Vinge, shall be appointed chairman at the
annual general meeting;
– that the number of members of the board shall be seven without deputies;
– that an audit firm shall be appointed as auditor;
– that the directors’ fees shall be paid with SEK 250,000 to the chairman of the board, with
SEK 125,000 to each of the other ordinary board members, with SEK 30,000 to the chairman
of the audit committee and SEK 15,000 to each of the other members of the audit committee,
and with SEK 30,000 to the chairman of the remuneration committee and SEK 15,000 to each
of the other members of the remuneration committee;
– that the fee to the auditor shall be paid in accordance with approved statement of costs;
– that the board members Michael Wolff Jensen, Hans Arwidsson, Maris Hartmanis, Carl-Johan
Spak and Torbjörn Koivisto are re-elected as board members and that Gunnar Gårdemyr and
Christine Lind are elected as new board members, for the period until the end of the next
annual general meeting;
– that Michael Wolff Jensen is re-elected chairman of the board; and
– that KPMG AB is elected as audit firm, in accordance with the board’s recommendation,
whereby KPMG has informed that Duane Swanson will be auditor in charge.
Information on the proposed board members
Gunnar Gårdemyr
Gunnar Gårdemyr is a Swedish citizen, born 1959. Gunnar Gårdemyr holds a Bachelor of Science
degree in marketing and finance from Lund University and degrees in business administration and
marketing management from Stockholm University. Gunnar Gårdemyr also has extensive experience
from different management positions in the global pharmaceutical industry (e.g. Takeda
Pharmaceuticals and Targovax ASA). Gunnar Gårdemyr is currently acting as CBO for Follicum AB and
is a member of the board of directors of RhoVac AB. Gunnar Gårdemyr holds 400 shares in Xspray
Pharma and is considered to be independent of Xspray Pharma, its management as well as Xspray
Pharma’s larger shareholders.
Christine Lind
Christine Lind is a US citizen, born 1974. Christine Lind holds a Bachelor of Science degree in finance
and information systems from New York University, Stern School of Business, and an MBA in finance
and management from Columbia Business School. Christine Lind has extensive experience from
management positions in the global biotech industry (e.g. LifeCell Corporation and Medivir AB) and as
a strategic and financial advisor to biotech and pharma companies (at Merrill Lynch & Co). Christine
Lind is currently CEO and chairman of the board of directors of Lind Growth Strategy AB. Christine Lind
does not hold any shares in Xspray Pharma and is considered to be independent of Xspray Pharma, its
management as well as Xspray Pharma’s larger shareholders.
Information regarding the individuals proposed by the nomination committee for re-election is
available at the company’s webpage www.xspraypharma.com.
Item 11 – Resolution on principles for the appointment of the nomination committee
The nomination committee proposes that the annual general meeting resolves on materially
unchanged principles for appointing the nomination committee, in accordance with the following.
The chairman of the board shall contact the three largest shareholders of the company in terms of
votes, according to Euroclear Sweden AB’s share register on 30 September. Each such shareholder shall
be offered the opportunity to appoint a member who shall, together with the chairman of the Board,
form the nomination committee. If any of these shareholders renounce from its right to appoint a
representative, the right to appoint such representative shall pass to the largest shareholder in turn in
terms of votes which is not already entitled to be represented on the nomination committee. The
procedure shall continue until the nomination committee consists of three members, excluding the
chairman of the board, if this can be achieved after contacts with the ten largest shareholders and
shareholders with a shareholding of three percent or more, as applicable, after which the thereby
appointed members shall form the committee. The chairman of the nomination committee shall be
the member who represents the largest shareholder in terms of votes, unless the members agree
otherwise. The chairman of the board may not be chairman of the nomination committee.
The chairman of the board shall convene the nomination committee to its first meeting and shall, as a
part of the nomination committee’s work, report to the nomination committee such circumstances
regarding the work of the board of directors and the need for special competences etc. that may be of
importance for the work of the nomination committee.
The composition of the nomination committee shall be announced as soon as the nomination
committee has been formed and in all events no later than six months before the next annual general
meeting. The members of the nomination committee are appointed for a term starting upon
announcement of the composition of the nomination committee and running until a new nomination
committee has been appointed.
In the event that the ownership structure of the company is changed after 30 September but before
announcement of the nomination committee’s complete proposals, and if a shareholder that after this
change has become one of the three largest shareholders in the company in terms of votes makes a
request to the chairman of the nomination committee to be part of the nomination committee, this
shareholder shall have the right to appoint an additional member of the nomination committee. The
nomination committee may further resolve that a member who has become significantly smaller than
the third largest shareholder in the company in terms of votes shall resign from the nomination
committee, if deemed appropriate.
If a member of the nomination committee resigns during the term of office or otherwise is unable to
continue as member, the nomination committee shall request the shareholder that had appointed that
member to, within reasonable time, appoint a new member. If the shareholder renounces its right to
appoint a member, the right to appoint such new member shall pass to the largest shareholder in turn
in terms of votes which is not already represented on, or has renounced its right to appoint a member
to the nomination committee. Changes to the composition of the nomination committee shall be
announced as soon as they occur.
The nomination committee shall prepare proposals in respect of the following issues for the next
annual general meeting to resolve upon:
chairman of the annual general meeting,
members of the board of directors,
chairman of the board of directors,
remuneration to the board of directors, distributed between the chairman of the board of
directors and the other members of the board of directors,
remuneration to the members of the remuneration committee and the audit committee, (if
applicable),
election of auditor,
remuneration to the auditor, and
in so far as it seems appropriate, changes to the procedures in force for the nomination committee.
No remuneration shall be paid to members of the nomination committee.
These instructions shall remain in force until the annual general meeting resolves otherwise.
Item 7b – Allocation of the company’s profit or loss according to the adopted balance sheet
The board of directors proposes that no dividends shall be executed for the financial year 2018.
Item 12 – Resolution to authorise the board of directors to issue new shares
Main proposal (item 12a)
The board of directors proposes that the annual general meeting resolves to authorise the board of
directors, at one or several occasions and for the period until the next annual general meeting, to
increase the company’s share capital by issuing new shares. Such share issue resolution may be made
with or without deviation from the shareholders’ preferential rights and with or without provisions for
contribution in kind or set-off or other conditions. The authorisation may only be utilized to the extent
that it corresponds to a dilution of not more than 20 per cent of the total number of shares outstanding
at the time of the general meeting’s resolution on the proposed authorisation.
The purpose of the authorisation is to increase the financial flexibility of the company and the general
flexibility of the board of directors. Should the board of directors resolve on a share issue with
deviation from the shareholders’ preferential rights, the reason for this shall be to ensure the
company’s continued development, finance an acquisition of operations, to procure capital to finance
the development of projects or to potentially broaden the shareholder base. Upon such deviation from
the shareholders’ preferential rights, the new issue shall be made at market terms and conditions.
The CEO is authorised to make such minor adjustments to this decision that may be necessary in
connection with the registration.
Alternative proposal (item 12b)
If the main proposal above does not meet the majority requirement at the annual general meeting,
the board of directors proposes that the annual general meeting authorises the board of directors to,
instead, issue new shares corresponding to a dilution of not more than 10 per cent of the total number
of shares outstanding at the time of the general meeting’s resolution on the proposed authorisation,
but on the same terms and conditions as stated in the main proposal above.
____________________
Majority requirements
A resolution in accordance with item 12a or 12b above requires approval of at least two thirds (2/3) of
the votes cast and the shares represented at the annual general meeting.
Other information
The shareholders are reminded of their right to require information in accordance with Chapter 7
Section 32 of the Swedish Companies Act. The annual report and the auditor’s report for the financial
year 2018, will be held available at the company’s office on Råsundavägen 12, SE-169 67 Solna,
Sweden, and on the company’s webpage www.xspraypharma.com, at least three weeks before the
meeting. Further, the nomination committee’s proposal and motivated statement will be available on
the address stated above as well as on the website stated above at least four weeks before the
meeting. Copies of the documents will be sent to the shareholders who so request and who inform the
company of their postal address. The company has its registered office in Solna.
For information on how your personal data is processed, see the integrity policy that is available at
Euroclear’s webpage www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammorengelska.
pdf.
_____________________
This is an in-official translation of the Swedish original wording. In case of differences between the
English translation and the Swedish original, the Swedish text shall prevail.
Solna, April 2019
Xspray Pharma AB (publ)
The Board of Directors
For further information, please contact:
Per Andersson, CEO, Xspray Pharma AB (publ)
Mobile: +46 (0) 706 88 23 48
E-mail: per.andersson@xspray.com
The information was submitted for publication, through the agency of the contact person set out above,
at 08.00 CEST on 24 April 2019.
About Xspray Pharma
Xspray Pharma AB (publ) is a product development company with several product candidates in clinical
development. Xspray Pharma uses its innovative patented RightSize technology to develop improved generic
versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment
is the second-largest in the field of oncology and drug prices are high. Through its innovative technology, Xspray
Pharma’s strategy is, through outlicensing to an appropriate pharmaceutical company, to enter the market as
first competitor to the original drugs before the exclusivity from secondary patents expires. Three PKIs have been
identified as the initial product candidates (HyNap-Dasa, HyNap-Sora and HyNap-Nilo). Xspray Pharma’s goal is
to have up to seven products ready for launch in the US market, where the first product to launch in 2021 will be
HyNap-Dasa. The substance patents for Sprycel®(dasatinib)*, expire in 2020 and the secondary patents expire in
2026, which can give Xspray Pharma’s HyNap-Dasa a five-year period of special position before other competitors
get access to the market. The company has patented manufacturing technology, equipment and the resulting
products. The shares in Xspray Pharma are traded on Nasdaq First North Stockholm.
Redeye AB is Xspray Pharma’s Certified Adviser
certifiedadviser@redeye.com
+46 (0)8 121 576 90